Featured Announcement:

BioSymetrics Selected to Present at MedTech Showcase™ During JP Morgan Healthcare Conference, January 8-10, 2018

January 2, 2018, New York—BioSymetrics Inc., a biomedical AI and machine learning company, today announced that Dr. Gabe Musso, Chief Scientific Officer, will present an overview of the Company’s business at the 2018 MedTech Showcase™ in San Francisco. He will also be available to hold one-on-one meetings with corporate partners and investors. The presentation will be webcast live and remain available for three months thereafter:

Date:  January 9, 2018

Time:  4:15 PM (Pacific Time) / 7:15PM (Eastern Time)

Location:  Parc 55 Hotel San Francisco – Union Square, 55 Cyril Magnin Street, 4th Floor

Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that BioSymetrics will be presenting at MedTech Showcase this year. Our conference is the perfect platform for life sciences, digital medicine, and health technology companies to showcase their innovation and seek out strategic alliances. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”

In AI market research and forecasts developed in 2017 by CB Insights, Forbes, McKinsey, and Frost & Sullivan, analysts project that global revenue opportunities for Machine Learning in life sciences, medicine and healthcare will exceed $6 billion within the next five years.

“Our dedicated team of data scientists has successfully built advanced AI platform technology in direct response to our customers’ needs to address many challenges and practical aspects of applying machine learning in life sciences, R&D and healthcare,” said Dr. Gabe Musso, CSO of BioSymetrics. “We are committed to making more sophisticated biomedical AI models and algorithms accessible to all R&D divisions of biopharmaceutical, healthcare, and precision medicine organizations.”

BioSymetrics leverages specialized end-to-end Machine Learning approaches for data pre-processing, feature selection, and down selection. Methods are outlined in a recent white paper on benchmarking of technologies used in data science for analysis of combined biomedical datasets.

###

About BioSymetrics Inc.

BioSymetrics is a biomedical AI (artificial intelligence) company that has built Machine Learning solutions to optimize innovation in life sciences and healthcare. We serve biopharmaceutical, genomics, diagnostic, healthcare, and technology companies. Our end-to-end machine learning platform, Augusta™, performs advanced data pre-processing and predictive analytics on complex biomedical datasets and large-scale massive data. Augusta can work from siloed or raw data, and enable integration of multiple biological, clinical, precision medicine, genomics, metabolomic, lab testing, and drug development data types. Augusta is deployable where the data reside, with fully dockerized distributed infrastructure that eliminates the need for transfer of sensitive data, and scalable architecture for enterprise and cloud computing applications. Our capabilities are underpinned by expertise in AI data science, predictive analytics, big data, medicine, bioinformatics, computational biology, advanced image processing, healthcare, and health IT. BioSymetrics is building the future of medical data science, and enabling customers to make sense of multi-modal, massive data. Founded in 2015, BioSymetrics is based in NY, Boston, and Toronto.

Additional information and links:

Wendy Tsai, VP Business Development – @biosymetrics on Twitter

Follow MedTech Showcase on Twitter: #DigiMedShowcase #BTS18 – @EBDGroup and @Demy_Colton